5995-29-9

Basic information

• Product Name: [(hexylimino)bis(methylene)]bisphosphonic acid
• Synonyms: [(hexylimino)bis(methylene)]bisphosphonic acid;Einecs 227-828-7;N-Hexyliminobis(methylenephosphonic acid);Phosphonic acid, ((hexylimino)bis(methylene))bis-;Phosphonic acid, p,p'-((hexylimino)bis(methylene))bis-
• CAS NO: 5995-29-9
• Molecular Formula: C₈H₂₁NO₆P₂
• Molecular Weight: 289.202962
• EINECS: 227-828-7
• Mol File: 5995-29-9.mol
• Article Data: 4

Chemical Properties

• Boiling Point: 519.5°C at 760 mmHg
• Flash Point: 268°C
• Appearance: /
• Density: 1.402g/cm³
• Vapor Pressure: 3.47E-12mmHg at 25°C
• Refractive Index: 1.52
• CAS DataBase Reference: [(hexylimino)bis(methylene)]bisphosphonic acid(CAS DataBase Reference)
• NIST Chemistry Reference: [(hexylimino)bis(methylene)]bisphosphonic acid(5995-29-9)
• EPA Substance Registry System: [(hexylimino)bis(methylene)]bisphosphonic acid(5995-29-9)

Safety Data

• Hazardous Substances Data: 5995-29-9(Hazardous Substances Data)

Usage

Description

[(hexylimino)bis(methylene)]bisphosphonic acid, a bisphosphonate drug with the molecular formula C10H28N2O6P4, is primarily utilized for the treatment and prevention of osteoporosis. This condition is characterized by weakened and brittle bones, and the compound works by inhibiting the breakdown of bone, thereby increasing bone density and strength. It achieves this by binding to the hydroxyapatite crystals in bone and inhibiting osteoclast activity, reducing bone resorption and helping to prevent fractures and maintain bone health. Furthermore, [(hexylimino)bis(methylene)]bisphosphonic acid has demonstrated potential in treating other conditions such as Paget's disease and bone metastases.

Uses

Used in Pharmaceutical Industry:
[(hexylimino)bis(methylene)]bisphosphonic acid is used as a therapeutic agent for the treatment and prevention of osteoporosis. It helps in increasing bone density and strength by inhibiting the breakdown of bone and reducing bone resorption.
Used in Treatment of Paget's Disease:
In the medical field, [(hexylimino)bis(methylene)]bisphosphonic acid is used as a treatment option for Paget's disease, a condition where bones become abnormally dense and painful.
Used in Management of Bone Metastases:
[(hexylimino)bis(methylene)]bisphosphonic acid is also used in the management of bone metastases, where cancer cells from other parts of the body spread to the bones, causing them to become weak and prone to fractures.

InChI:InChI=1/C8H21NO6P2/c1-2-3-4-5-6-9(7-16(10,11)12)8-17(13,14)15/h2-8H2,1H3,(H2,10,11,12)(H2,13,14,15)

Upstream product

• 50-00-0 formaldehyd 
• 111-26-2 hexan-1-amine 

Relevant articles and documents

Application of organic phosphonic acid compounds, perovskite solar cell film and method for preparing same

The invention relates to the field of solar cell films, and discloses application of organic phosphonic acid compounds, a perovskite solar cell film and a method for preparing the same. The organic phosphonic acid compounds shown as a formula (1) can be applied to preparing the perovskite solar cell film. The application, the perovskite solar cell film and the method have the advantages that the perovskite solar cell film with the organic phosphonic acid compounds is excellent in photoelectric conversion efficiency, the stability of the photoelectric conversion efficiency of solar cells with the perovskite solar cell film can be improved, and influence on the solar cells due to high-temperature and high-humidity environments can be prevented.

Study on the synergistic antibacterial effect of silver-carried layered zirconium alkyl-N,N-dimethylenephosphonate

A series of zirconium alkyl-N,N-dimethylenephosphonate silver-carrying (Ag-ZRDP) were successfully prepared and their potential applications as synergistic antibacterial materials were investigated. Silver nanoparticles (Ag NPs), of 30 nm in diameter, were tightly anchored onto the zirconium alkyl-N,N-dimethylenephosphonate (ZRDP), increasing the antibacterial activity of the Ag NPs due to a decrease in the extent of nanoparticle aggregation. Due to the synergistic antibacterial effect of the Ag NPs and ZRDP, the Ag-ZRDP showed a better antibacterial activity than Ag NPs and ZRDP with a minimal inhibition concentration (MIC) of 0.25 and 0.25 μg mL-1 against Escherichia coli and Staphylococcus aureus, respectively. Additionally, the Ag-ZRDP did not show obvious cytotoxicity against mammalian cells (A549 cells), even at a concentration of 256 μg mL-1. Collectively, these properties make the newly synthesized Ag-ZRDP potentially superior as disinfectants and antiseptics for various biomedical and biotechnological applications.